The Radiopharmaceuticals Market is characterized by a dynamic competitive landscape featuring established industry leaders and emerging specialized players. Key companies include Cardinal Health (US) , GE Healthcare (GB) , Bayer AG (DE) , Novartis AG (CH) , Siemens Healthineers (DE) , Elekta AB (SE) , Lantheus Medical Imaging (US) , Bracco Imaging S.p.A. (IT) , and NorthStar Medical Radioisotopes, LLC (US) . These companies compete through innovation, strategic acquisitions, global expansion, and continuous investment in research and development.
Novartis AG has emerged as a dominant force in therapeutic radiopharmaceuticals following its acquisitions of Advanced Accelerator Applications (AAA) and Endocyte, gaining key products Lutathera (Lu-177 DOTATATE) and Pluvicto (Lu-177 PSMA-617). In January 2024, Novartis obtained FDA approval for the commercial production of Pluvicto at its new radioligand manufacturing facility in Indianapolis, expanding its production capacity to meet growing demand.
Bayer AG is a leader in alpha-emitter therapy with its product Xofigo (radium-223), used for metastatic castration-resistant prostate cancer. The company continues to invest in its radiopharmaceutical pipeline, leveraging its expertise in nuclear medicine. GE Healthcare and Siemens Healthineers are leaders in imaging technology, providing PET/CT and SPECT/CT systems that are essential for radiopharmaceutical applications, and they are increasingly integrating AI and digital solutions into their imaging platforms.
Recent industry developments reflect significant consolidation and investment in the sector. In March 2024, AstraZeneca acquired Fusion Pharmaceuticals for USD 2.4 billion, gaining access to its FPI-2265 prostate cancer radioconjugate and manufacturing assets. In February 2024, Bristol-Myers Squibb finalized its USD 4.1 billion acquisition of RayzeBio, bolstering its actinium-based radiopharmaceutical pipeline. In November 2025, Curium—a leading radiopharma manufacturer—was recapitalized by CapVest Partners LLP in a deal valuing Curium at approximately USD 7 billion, described as the largest transaction in nuclear medicine globally.
The competitive landscape is characterized by strategic partnerships between pharmaceutical companies and research institutions, as well as investments in manufacturing capacity to ensure reliable supply of medical isotopes. As the market continues to grow, competitive differentiation is expected to shift toward innovation in novel radiotracers, development of alpha-emitter therapies, and supply chain reliability.